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Abstract: Cancer is considered as one of the deadliest diseases in the medical field. Apart 
from the preventive therapies, it is important to find a curative measure which holds no 
loopholes and acts accurately and precisely to curb cancer. Over the past few decades, 
there have been advances in this field and there are many antitumor compounds available 
on the market, which are of natural as well as synthetic origin. Marine chemotherapy is 
well recognized nowadays and profound development has been achieved by researchers to 
deal with different molecular pathways of tumors. However, the marine environment has 
been less explored for the production of safe and novel antitumor compounds. The reason 
is a number of shortfalls in this field. Though ample reviews cover the importance and 
applications of various anticancerous compounds from marine natural products, in the 
present review, we have tried to bring the current status of antitumor research based on 
marine inhibitors of cancer signaling pathways. In addition, focus has been placed on the 
shortfalls and probable strategies in the arena of marine antitumor drug discovery.  
Keywords: marine antitumor compounds; cancer signaling pathways; shortfalls in cancer 
research; clinical status of antitumor drugs 
 
1. Introduction  
Cancer has posed a great challenge to the fields of medicine and immunology. Finding novel and 
efficient compounds of natural origin has been a major point of concern for research in the 
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pharmaceutical sciences. Nature harbors a vast variety of flora and fauna including microbial 
inhabitants and lithosphere, atmosphere and hydrosphere cumulatively provide an excellent source of 
chemically diverse compounds with great therapeutic potential. Drugs derived from natural products 
have a giant impact on the antitumor drug discovery regime of the present day [1]. This importance of 
natural products in the field of therapeutics may be attributed to their high affinity to the target, little 
loss of entropy when they bind to a protein and their bioavailability. Moreover, natural compounds are 
quite flexible in conformational acquisition in aqueous and lipophilic environments [2]. 
The oceanic environment has been a vast source of such natural compounds covering a wide range 
of bioactivity such as photoprotective [3], antihelmintic, antibacterial, anticoagulant, antifungal,   
anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, antiviral and other miscellaneous 
mechanisms of action [4]. For the past two decades, marine pharmaceutics has been a developing field 
in the antitumor drug development arena. Marine organisms including sponges [5,6], sponge-microbe 
symbiotic association [7], gorgonian [8], actinomycetes [9], and soft coral [10] have been widely 
explored for potential anticancer agents.  
Despite an array of antitumor compounds that have been produced from the marine environment, a 
vast majority of oceanic habitat is underexplored due to various problems faced by marine 
biotechnologists and pharmacists. First, the marine natural products are large in molecule size and 
complex in structure with multiple chiral centers. Second, lack of technological innovations and 
financial support coupled with environmental considerations pose hindrances to marine antitumor drug 
research. Some speedy expansions in molecular biology, bioengineering, genomics, proteomics and 
metabolomics have aided the discovery of natural products and their implication in antitumor   
drug development.  
This review showcases recent developments in the field of marine antitumor research with emphasis 
on the signal transduction pathways of oncogenesis, clinical status of the marine derived antitumor 
compounds and discusses the potential challenges and probable strategies to combat the gap between 
marine compound isolation and successful antitumor drug development. It is an attempt to focus the 
attention of the scientific community including biologists and chemists on an integrative approach 
towards antitumor drug development from marine sources 
Figure 1. Chemical structures of some marine derived antitumor compounds. The 
corresponding references have been superscripted after the compound name [11–25]. 
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Figure 1. Cont. 
 
2. Marine Drugs against Major Players in Cancer 
Carcinogenesis is a complex process controlled by various signal transduction pathways linked to 
processes such as inflammation, cell differentiation and survival, and metastasis. Most of the players of 
these pathways are interrelated and irregularities in their crosstalk result in impairment of cellular 
functions leading to tumor generation and progression. Few such players have been targeted for cancer 
therapy and some inhibitors from marine sources have been designed and studied to counteract tumor 
progression and curb carcinogenesis. Some such studies are reviewed in this section. Mar. Drugs 2010, 8                 
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2.1. MMP Inhibitors 
Matrix metalloproteinases (MMPs), zinc dependant endopeptidases that degrade the extracellular 
matrix (ECM) [26], have been extensively focused on due to their evident role in carcinogenesis and 
cellular invasion by catabolizing the extracellular matrix [27]. Apart from playing a major role in 
invasion, angiogenesis, and metastasis during tumor progression, MMPs are also important for cancer 
cell transformation, growth, apoptosis, signal transduction and immune regulation [28,29]. Marine 
sources have been extensively explored for potential MMP inhibitors [30]. Kim et al. (2006) reported 
the inhibitory effect of marine derived chitooligosaccharides (COS) on the activation and expression of 
matrix metalloproteinase-2 (MMP-2) in primary human dermal fibroblasts (HDFs). They found that 
medium molecular weight COS (3–5 kDa) exhibited highest inhibitory effects by reducing the gene 
expression and transcriptional activity of MMP-2 [31].  
Further, Quang et al. (2006) investigated the effect of low molecular weight COS (1–3 kDa) on the 
activity and expression of MMP-9 in HT1080 cells and confirmed the inhibition by gelatin 
zymography [32]. To understand the molecular basis of the MMP-9 inhibitory effect of COS, 
Rajapakse et al. evaluated carboxylated chitooligosaccharides (CCOS) on human fibrosarcoma cell 
line. A clear dose-dependent inhibition on MMP-9 mediated gelatinolytic activities were observed in 
HT1080 cells following the treatment with CCOS in zymography experiments. Transfection studies 
carried out with MMP-9 and AP-1 reporter constructs suggested that the observed reduction in MMP-9 
expression was due to down-regulation of MMP-9 transcription mediated via inhibition of AP-1. 
However, in the presence of CCOS, NF-κB and TIMP-1 expression levels remained constant [33]. 
Wang et al. (2008) isolated the sulfated S. maindroni ink polysaccharide (SIP-SII) from cuttlefish 
Sepiella maindroni and examined the effects of SIP-SII on the expression of matrix metalloproteinases 
MMP-2 and MMP-9 as well as tumor cell invasion and migration. SIP-SII (0.8–500 mg/mL) 
significantly decreased the expression of MMP-2 activity in human ovarian carcinoma cells SKOV3. 
No significant decrease of MMP-9 activity was detected in the cell line after SIP-SII treatment [34]. 
MMP inhibitory effects of phlorotannins from marine brown algae Ecklonia cava (EC) have also been 
studied. Fluorometric assay revealed that EC extract could specifically inhibit both MMP-2 and   
MMP-9 activities significantly (P < 0.001) at a concentration of 10 μg/mL in human dermal fibroblasts 
and HT1080 cells. In addition, EC extract did not exert any cytotoxic effect even at 100 μg/mL, 
proposing its potential use as a safe MMP inhibitor [35]. 
2.2. HIF Inhibitors 
To design effective drugs against cancer, it is mandatory to understand the underlying tumor 
physiology and the changes occurring in the tumor microenvironment [36]. It has been observed that 
tumor progression is associated with not only increased microvascular density but also intratumoral 
hypoxia [37]. Further, loss of HIF-1 activity has been shown to have immense negative effects on 
tumor growth, vascularization and energy metabolism in xenograft assays [38,39]. Thus a number of 
HIF inhibitors have been designed with the aim of finding new direction to tumor therapy. 
Laurenditerpenol, isolated from bioassay-guided fractionation of the lipid extract of the red alga 
Laurencia intricata Lamouroux (Rhodomelaceae), yielded the first marine natural product that Mar. Drugs 2010, 8                 
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inhibited HIF-1 activation [40]. It was shown to inhibit HIF-1 activation by blocking hypoxia-induced 
HIF-1 protein accumulation and suppressed mitochondrial oxygen consumption at ETC complex I at 
an IC50 value of 0.8 µM.  
In search of potent and selective small-molecule HIF-1 inhibitors, Liu et al. (2007) observed 81% 
inhibition of hypoxia-induced HIF-1 activation by the crude extract of the sponge Dendrilla nigra 
(Aplysillidae) at a concentration of 5 μg/mL. The study was carried out using T47D human breast 
carcinoma cell-based reporter assay and the bioassay-guided chromatographic separation yielded four 
new lamellarin-like phenolic pyrroles that bear structural features similar to Lamellarin O [41]. A year 
later, the same group identified and characterized a structurally unique inhibitor of HIF-1 activation, 
Furospongolide (IC50 2.9 μM, T47D breast tumor cells) from a marine sponge Lendenfeldia sp. One 
new cytotoxic scalarane sesterterpene was also reported from the same extract. They found that 
Furospongolide blocked the induction of the downstream HIF-1 target secreted vascular endothelial 
growth factor (VEGF) and suppressed HIF-1 activation by inhibiting the hypoxic induction of HIF-1 
protein. It was found to suppress tumor cell respiration via the blockade of NADH-ubiquinone 
oxidoreductase (complex I)-mediated mitochondrial electron transfer [42].  
Lipid extract of the crinoid Comantheria rotula (Comasteridae) yielded seven Benzo[g]chromen-4-
one and Benzo[h]chromen-4-one pigments. The crinoid’s pigments significantly inhibited both 
hypoxia-induced (IC50 values 1.7–7.3 μM) and iron chelator-induced HIF-1-dependent luciferase 
reporter activity (IC50 values 0.6 to 3.0 μM) in T47D cells. Four of these pigments were also reported 
to significantly suppress HIF-1 activation in PC-3 prostate tumor cells [43]. A number of other 
structurally diverse marine natural product-derived HIF inhibitors including Manassantin B [44],   
7-hydroxyneolamellarin A [41] have also been discovered in past some years. An extensive review 
published last year covers most of the information on HIF inhibitors of natural origin including 
compounds from marine algae and marine organisms [45]. 
2.3. Nuclear Factor-B Inhibitors 
Nuclear factor-B (NF-B) is a ubiquitous transcription factor, a dimer of proteins of the Rel family 
including NF-B1 (p50), NF-B2 (p52), RelA (p65), RelB and c-Rel [46], whose deregulated 
expression may lead to cancer (Figure 2). NF-B is activated by various stimuli, including TNF- 
(tumor necrosis factor-), interleukin-1 and lipopolysaccharide [47]. Certain fungal metabolites show 
promising potential as novel anti-cancer agents as they modulate the activity of NF-κB. Folmer et al. 
(2008) divided NF-B inhibitors into four categories: (a) compounds targeting the IKK-dependent 
degradation of IkB, (b) compounds specifically interfering with the proteolytic activity of the 26S 
proteasome, (c) compounds interfering with the binding of NF-B to its DNA binding site, and (d) 
compounds with unknown mechanisms of action [48]. Marizomib (Salinosporamide A; NPI-0052), a 
proteasome inhibitor isolated from a marine bacterium Salinispora tropica, has a great potential as an 
anticancer drug [49]. A study published last year reported three new cyclohexadepsipeptides, 
Arenamides (A-C) from the fermentation broth of a marine bacterial strain Salinispora arenicola. They 
studied the effect of Arenamides A and B on NF-B activity with stably transfected 293/NF-B-Luc 
human embryonic kidney cells induced by treatment with tumor necrosis factor (TNF). It was observed Mar. Drugs 2010, 8                 
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that Arenamides A and B blocked TNF-induced activation of NF-B in a dose- and time-dependent 
manner [50].  
Even marine derived sediments are rich in bioactive substances which may prove to be potential 
NF-B inhibitors. Nam and coworkers (2010) have recently isolated Fijiolide A, a potent inhibitor of 
TNF--induced NF-B activation, from a marine-derived bacterium of the genus Nocardiopsis. It was 
observed to reduce TNF--induced NF-B activation by 70.3%, with an IC50 value of 0.57 µM. Their 
data proposes Fijiolide A as a promising lead for more advanced anticancer testing [51]. The biological 
effects of Heteronemin, a marine sesterterpene isolated from the sponge Hyrtios sp., were studied 
recently by Schumacher and colleagues on chronic myelogenous leukemia cells. In their observation, 
heteronemin inhibited both trypsin and chymotrypsin-like proteasome activity at an IC50 value of   
0.4 µM thereby inhibiting NF-B activation and proving to be detrimental to cancer cells via   
apoptosis [52]. 
Figure 2. R o l e  o f  T N F -  induced NF-B in carcinogenesis. During inflammation,   
TNF- induced NF-B acts on proliferating cells thereby causing their malfunction and 
leading to cancer. 
 
2.4. Topoisomerase Inhibitors 
Topoisomerases play a major role in maintaining the integrity of the DNA helix during replication, 
transcription, and chromosome condensation in mitosis [53] and thus are important for cell 
proliferation. They are now being targeted for anticancer therapy. Over the past three decades, 
numerous topoisomerase inhibitors have been isolated from various natural sources, in order to find an 
effective anticancer drug. These agents either prevent the formation of covalent bonds between 
topoisomerase and DNA or stabilize the intermediate topoisomerase-DNA covalent binary complex 
thus preventing DNA relegation. They preclude DNA replication and transcription, and thereby lead to 
the death of cells attempting to undergo these processes (Figure 3). Mar. Drugs 2010, 8                 
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Figure 3. Schematic representation of the mode of action of Topoisomerase inhibitors by 
(A) preventing covalent bond formation or (B) preventing DNA resealing.   
Here,   represents Topoisomerase enzyme and   represents Topoisomerase inhibitor. 
 
Makaluvamine A is a pyrroloquinoline, principally isolated from the sponge Zyzzya fuliginosa and 
is known to have potent anticancer activity via inhibiting topoisomerase II [54]. Ascididemin (ASC) is 
an aromatic alkaloid isolated from the mediterranean ascidian Cystodytes dellechiajei [55], which has 
been shown by Dassonneville and coworkers as a strong inducer of apoptosis in HL-60 and P388 
leukemia cells. Through relaxation assays using supercoiled DNA, they showed that ASC stimulated 
double-stranded cleavage of DNA by topoisomerase II, but exerted only a very weak effect on 
topoisomerase I [56]. Yet another alkaloid, Lamellarin D (LAM-D), initially isolated from a 
prosobranch mollusc of the genus Lamellaria, has been recently shown to target topoisomerase I. 
Tardy et.al. (2004) conducted studies at the molecular and cellular levels to determine the mechanism 
of action of this alkaloid and concluded that LAM-D potently stabilizes topoisomerase I–DNA 
covalent complexes so as to promote the formation of DNA single strand breaks [57]. 
2.5. PKC Inhibitors 
Members of the protein kinase C (PKC) family of serine/threonine kinases are known to be major 
players in oncogenesis. One of the isoforms, PKCε, has been demonstrated to increase proliferation, Mar. Drugs 2010, 8                 
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motility, and invasion of fibroblasts or immortalized epithelial cells. It has been proven in xenograft 
and transgenic animal models that overexpression of PKCε is tumorigenic, resulting in metastatic 
disease [58]. The marine environment has provided a very efficient class of PKC inhibitors, known as 
Bryostatins. These are highly oxygenated marine macrolides with a unique polyacetate backbone. 
Since their discovery from the marine animal Bugula neritina in 1982 [59], and showing high activity 
against the murine P388 lymphocytic leukemia, 20 natural Bryostatins are a part of our knowledge 
today [60]. Their low toxicity and antineoplastic nature makes them promising candidates for cancer 
chemotherapeutics. Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds 
to the regulatory domain of protein kinase C. Short-term exposure to Bryostatin-1 promotes activation 
of PKC, whereas prolonged exposure promotes significant downregulation of PKC. It has been 
reported that Bryostatin-1 inhibits proliferation, induces differentiation, and promotes apoptosis in 
numerous hematological and solid tumor cell lines [61]. It has been proven to be such a promising 
candidate that it is being evaluated as an antitumor agent against myeloma, acute myeloid leukemia, 
chronic lymphocytic leukemia (CCL), AIDS-related lymphoma, non-Hodgkin's lymphoma, colorectal, 
renal, prostate, head and neck, cervix, ovarian, breast, peritoneal, stomach, esophagus, anus and   
non-small cell lung cancer [60]. Studies are now underway to understand the chemical basis of the 
biological activity of Bryostatins. Keck et al. (2009) prepared a close structural analogue of 
Bryostatin-1, which differs from it only by the absence of the C (30) carbomethoxy group (on the C 
(13) enoate of the B-ring), by total synthesis. They further attributed the biological properties of 
Bryostatin-1 to the substitution in the A-ring [62]. 
3. Clinical Status of Marine Derived Antitumor Drugs  
Although the number of natural products is increasing day by day, very few compounds find their 
way to the market. This may be due to many factors, particularly the cytotoxicity that they show on 
normal human cell lines, rendering the compound unfit for use as medicinal supplement. Despite the 
failure rate, some potential compounds have shown promising results as antitumor agents in preclinical 
trials and many have made it to different phases of clinical trials. Some of them have already been 
approved as potent anticancer drugs and are already on the market. Cytarabine, Ara-C (Cytosar-U
®), a 
DNA polymerase inhibitor is one such drug developed by Bedford laboratories and Enzon 
pharmaceuticals, which has been approved for use as an antitumor agent. Trabectedin or Ecteinascidin 
743 (Yondelis
®), an alkaloid of tunicate origin, has been approved in European countries to be used for 
the treatment of soft tissue sarcoma [20]. With an integrated approach of microbiology, screening and 
natural products chemistry, the marine microbial metabolites are now advancing to be the 
pharmaceutically important drug candidates. Many compounds of different chemical class and with 
different mechanisms of action are under clinical trials to prove their potential as antitumor drugs 
(Table 1).  Mar. Drugs 2010, 8                 
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Table 1. Clinical status of marine derived antitumor agents, their chemical class and mode 
of action. 
Compound Name  Chemical Class  Organism  Mode of action  Company  Status 
Cytarabine, Ara-C  Nucleoside  Sponge  DNA Polymerase Inhibitor  Bedford, Enzon  Approved 
Trabectedin (ET-743)  Alkaloid  Tunicate  Cell cycle arrest  PharmaMar  Approved 
Eribulin Mesylate 
(E7389) 
Macrolide  Sponge  Microtubule interfering agent  Eisai Inc.  Phase III 
Soblidotin (TZT 1027)  Peptide  Bacterium  Microtubule interfering and 
vascular disrupting agent 
Aska 
Pharmaceuticals 
Phase III 
Squalamine lactate  Aminosteroid  Shark  Calcium binding protein 
antagonist 
Genaera  Phase II 
Cemadotin  Peptide  Sea slug  Microtubule interfering agent  Knoll  Phase II 
Plinabulin (NPI-2358)  Diketopiperazine  Fungus  Vascular disrupting agent  Nereus 
Pharmaceuticals 
Phase II 
Plitidepsin  Depsipeptide  Tunicate  Apoptosis inducer  PharmaMar  Phase II 
Elisidepsin  Depsipeptide  Mollusc  -  PharmaMar  Phase II 
Zalypsis  Alkaloid Nudibranch  Cell  cycle arrest  PharmaMar  Phase II 
Tasidotin, Synthadotin 
(ILX-651) 
Peptide  Bacterium  Microtubule interfering agent  Genzyme 
Corporation 
Phase II 
Discodermolide  Polyketide  Sponge  Microtubule interfering agent  Novartis  Phase I 
HT1286  Dipeptide  Sponge  Microtubule interfering agent  Wyeth  Phase I 
LAF389  Amino acid 
derivative 
Sponge Methionine  aminopeptidase 
inhibitor 
Novartis Phase  I 
Kahalalide F  Cyclic depsipeptide  Sea slug/alga  Lysosomotropic   PharmaMar  Phase I 
KRN7000  -galactosylceramide Sponge  Immunostimulatory    Kirin  Phase  I 
Bryostatin 1  Polyketide  Bacterium/ Bryozoa  PKC isozyme inhibitor  National Cancer 
Institute 
Phase I 
Hemiasterlin (E7974)  Tripeptide  Sponge  Microtubule interfering agent  Eisai Inc.  Phase I 
Marizomib, 
Salinosporamide A;  
NPI-0052) 
Beta-lactone-gamma 
lactam 
Bacterium  Proteasome inhibitor  Nereus 
Pharmaceuticals 
Phase I 
LY355703, CRYPTO 52  Cryptophycin  Cyanobacterium  Microtubule interfering agent  -  Preclinical 
Depsipeptide (NSC 
630176) 
Bicyclic peptide  Cyanobacterium  Histone deacetylase inhibitor  -  Preclinical 
Eribulin mesylate (E 7389), a macrolide natural product isolated from marine sponges [63] is shown 
to be a promising microtubule interfering agent leading to cell death by apoptosis [64] and is currently 
under Phase III clinical trials. Another natural compound under Phase III clinical trials is a peptide 
Soblidotin (TZT-1027), derived from a marine bacterium [20]. It acts in a dual manner by inhibiting 
tubulin assembly and disrupting the vasculature of tumor cells, causing them to collapse [65]. Apart 
from Squalamine lactate, an aminosteroid obtained from shark, and Cemadotin, a peptide obtained 
from sea slug, few other compounds are under Phase II clinical trials. These include Plitidepsin 
(Aplidin
®), a marine depsipeptide from tunicate Aplidium albicans, which is a potent apoptosis inducer 
as depicted in both in vitro and in vivo studies [66]. Yet another compound is a diketopiperazine 
known as Plinabulin (NPI-2358), isolated from a marine alga associated Aspergillus sp CNC-139 [67]. Mar. Drugs 2010, 8                 
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This compound also inhibits tubulin assembly and acts as a vasculature disrupting agent that 
destabilizes the tumor vascular endothelial architecture and leads to cell damage [68]. 
Bryostatin 1, a polyketide isolated initially from Bryozoa, is now known to be produced by its 
bacterial symbioant, Candidatus Endobugula sertula [69]. It basically works as a PKC isozyme 
inhibitor and is currently under Phase I clinical trial under the aegis of the National Cancer Institute 
(USA) [20]. Another fungal symbioant, Penicillium chrysogenum of the marine sponge Ircinia 
fasciculata produces an antileukemic agent- Sorbicillactone-A, which has qualified now for human 
trials, owing to its amazing anticancer properties [70]. Marizomib (Salinosporamide A; NPI-0052) 
Salinosporamide A, a proteasome inhibitor isolated from a marine bacterium Salinispora tropica [49], 
is also undergoing Phase I clinical trials under the auspices of Nereus Pharmaceuticals (San Diego, 
CA). Interesting properties such as a broader and longer lasting proteasome inhibition, efficacy against 
a wider range of hematologic malignancies and many solid tumor models, less cytotoxicity to normal 
cells, higher in vivo potency and potential for both oral and intravenous administration makes 
Salinosporamide A a very promising anticancer agent [71]. Two natural products of cyanobacterial 
origin (LY355703, CRYPTO52 and Depsipeptide (NSC 630176) are under preclinical trials. 
Depsipeptide (NSC 630176) is a bicyclic peptide isolated from Chromobacterium violaceum. It is 
known to decrease mRNA expression of the c-MYC oncogene thereby causing cell-cycle arrest at  
G0–G1 [72]. 
4. Shortfalls in Marine Antitumor Drug Research 
Although much development has been achieved in the fields of biomedicine and pharmaceutical 
sciences, still very few natural products have found their way to the market till date. There are ample 
reasons that may be affecting this shortfall, including; lack of sufficient amount of natural product, 
difficulties in accessing the source of the samples, problems associated with harvesting of the product, 
troubles in synthesizing the necessary amounts of the compound, difficulties in isolation and 
purification procedures, high toxicity of the active compound, ecological considerations, government 
policies, lack of infrastructure and insufficient capital investment. 
For example, studies on the marine HIF inhibitor Laurenditerpenol were hindered by a lack of 
compound supply [45]. Many species of microorganisms produce specific metabolites at specific 
phases of their growth. A slight alteration in the culture parameters may lead to changes in the amount 
and type of metabolite produced thus leading to insufficient supply of the compound. As mentioned 
earlier in this review, topoisomerase plays a major role in cancer. A new isoform-human 
topoisomerase III, identified a couple of years ago [73],  cleaves single-strand DNA and binds 
covalently to the 5’-end of the cleaved DNA [74]. Even eight years after its discovery, there are yet no 
specific inhibitors for topoisomerase III. In addition to this, a recent article in Nature throws light on 
the dual action of HIF- in different conditions, which poses a question for its use as a molecular 
target for cancer therapy [75]. 
A number of marine microorganisms are difficult to culture and lack of literature on the isolation 
procedures and standardized culture conditions makes the situation even worse, with less numbers of 
academics undertaking such studies. For instance, despite the fact that the marine actinomycetes may 
be a storehouse of novel bioactive molecules, different from terrestrial counterparts, they are an Mar. Drugs 2010, 8                 
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underexploited source for the discovery of novel secondary metabolites [76], the main reason being the 
lack of efforts spent in exploring them. In addition, the fact that the terrestrial actinomycetes produce 
resistant spores which get transported from land to oceans, where they can remain available but 
dormant for many years, has made researchers more skeptical for the existence of indigenous 
populations of marine actinomycetes [77]. Thus, the myth prevails that marine actinomycetes are 
originally terrestrial. This lack of knowledge prevents uncovering of the vast potential of marine 
actinomycetes.  
A lack of understanding of cancer biomarkers (major players in carcinogenesis and tumor 
progression) is also a major shortfall in harnessing the marine environment for specific tumor targeting 
drugs. Despite a vast array of technologies in cancer research with unprecedented depths of analyses, 
the complexity of cancer proteomics and the underlying altered signaling pathways pose a great 
challenge for marine antitumor drug research. There is an imperative need for extensive, integrative 
and collaborative endeavors to explicate proteome alterations in cancer [78]. Moreover, even after 
knowing the targets and the development of novel marine drugs against the same, fewer and fewer 
breakthrough ideas find their way out of research institutions and into the hands of experienced 
clinicians and medical product development teams as the promising research and innovation are not 
being translated into new treatments. The increasing drug resistant mutations in cancer causing 
microbial agents, further leads to the lesser number of antitumor drugs in the market. 
Certain other issues that pose an obstacle to the marine antitumor drug research include lack of 
funding and infrastructure resources and experience in the biotechnology firms to perform the 
extensive late-stage clinical development programs that are needed for regulatory approval of a drug. 
The reluctance of large pharmaceutical companies to invest in early-stage research raises another 
financial setback for marine natural product research. It may be because of the lack of surety of 
novelty and proven market potential; moreover, it even requires a longer period of time for the 
investments to be actually returned in terms of profit. The huge structural diversity of marine natural 
compounds makes it difficult for the isolation and purification of these compounds and the 
development of novel antitumor drugs from these natural sources possesses problems that are not 
usually met when one deals with synthetic compounds.  
Prevailing threats to global marine biodiversity including overfishing, habitat loss, invasive species 
and pollution, rising water temperatures and ocean acidification are further making marine antitumor 
drug research more and more difficult. 
5. Strategies to Combat the Pitfalls 
The discovery of modern anticancer drugs aims to search for improved cytotoxic agents in terms of 
the accuracy, efficacy and target specificity and sensitivity. The vast biodiversity of the marine 
environment can serve as a rich source of such natural compounds. However, keeping the above 
mentioned challenges in view, it becomes mandatory to design specific strategies for improvement of 
their therapeutic potential. 
A semisynthetic approach could be one of the alternatives to enhance the yield of lead natural 
compounds. It can be achieved by modifying the functional groups of existing natural compounds. 
This would lead to the generation of structural analogues with greater pharmacological activity and Mar. Drugs 2010, 8                 
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with fewer side effects. For example, studies on the marine HIF inhibitor Laurenditerpenol were 
hindered by a lack of compound supply. However, a recently completed total synthesis has resolved 
the absolute configuration of Laurenditerpenol [79] and together with other synthetic efforts [80] may 
provide sufficient compound to allow further evaluation. A more integrated approach comprising   
high-throughput screening methods, computational biology and bioinformatics may be useful in 
producing compounds that are more efficient than the ones that are prevalent today. Increasing use of 
genomics and implication of combinatorial biosynthesis can be applied for discovery and modification 
of natural marine microbial products.  
Marine fungi are prolific producers of bioactive compounds including antitumor drugs [81–83]. A 
more intrinsic insight in the biology and interspecies relationship of marine fungi would help for better 
understanding of the kind of compounds that may be isolated from them. As per Raghukumar (2008), a 
more systematic research should be initiated for fungi from deep-sea, hypoxic zones (with low oxygen 
levels) and hydrothermal vents for enzymes, degradation of xenobiotics and bioremediation 
applications. He further suggested that genomic and proteomic studies with novel organisms such as 
Corallochytrium limacisporum as a model of animal fungal allies will hopefully help in basic research 
on evolutionary biology [84]. Macrofungi has already been a great source of anticancer agents [85]. An 
evolutionary approach coupled with an ecological perspective can do wonders in the field of marine 
natural product discovery and a careful approach in this field can lead to increased production of 
bioactive compounds with high efficiency. Another effective strategy would be molecular modification 
for example, implication of ribosome engineering to develop mutant strains that overproduce 
secondary metabolites by screening various drug-resistance mutations. The efficacy of the strain 
improvement has recently been highlighted in Streptomyces sp. by introducing combinatory   
drug-resistances [86].  
Targeted therapy has been an indispensable approach towards oncogenic signaling pathways.   
Drug-specific modulation of oncogenic signaling pathways in specific patient subpopulations can 
predict responsiveness to targeted therapy. Andersen et al. (2010) recently reported a pathway-based 
phosphoprofiling approach to identify and quantify clinically relevant, drug-specific biomarkers for 
phosphatidylinositol 3-kinase (PI3K) pathway inhibitors that target AKT, phosphoinositide-dependent 
kinase 1 (PDK1), and PI3K–mammalian target of rapamycin (mTOR) [87]. Another alternative would 
be to improvise different targeted cancer proteome projects and initiatives with clearly delineated 
objectives. Advances in the field of proteomics, genomics and metabolomics are integral to cell 
metabolism and have great impact on the identification of new antitumor targets. Not only this, there 
are newer fields of biology, such as pharmacogenomics and pharmacogenetics, which are proving to 
be very helpful for understanding patient susceptibility to specific pharmacological agents.  
As far as the problems associated with HIF are concerned, Semenza (2002) suggested that the 
combination of an anti-angiogenic agent and an inhibitor of HIF-1 might be particularly efficacious, as 
the angiogenesis inhibitor would cut off the tumor’s blood supply and the HIF-1 inhibitor would 
prevent the ability of the tumor to adapt to the ensuing hypoxia and thus the efficacy of HIF inhibitor 
may be greatly enhanced [36]. As suggested by Borkakoti (2004), the use of MMP inhibitors in 
combination therapy and in early stages of disease onset, could be a novel approach geared towards 
achieving improved clinical advantage [88].  Mar. Drugs 2010, 8                 
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6. Conclusions 
One of the greatest challenges for the field of medicine and immunology is finding a sure shot cure 
for cancer. An extensive research regime needs to be started to combat the ability of cancer cells to 
mutate and become resistant to available drugs. As mentioned above, collaborative scientific 
approaches with a focus on molecular mechanisms of tumorigenesis need to be initiated. Efforts are 
required to gain deeper knowledge regarding the various signal transduction pathways linked to 
cellular processes such as inflammation, cell differentiation and survival, carcinogenesis, and 
metastasis. Although it is very difficult to predict the final outcome of such a scheme of drug 
discovery, it can be assured that a focused approach and combined efforts would definitely accelerate 
the development of new marine antitumor drugs to be discovered with increased efficiency.  
Acknowledgements 
This research was supported by Marine Bioprocess Research Center of the Marine Bio 21 center 
funded by the ‘Ministry of Land, Transport and Maritime’, Republic of Korea. The authors are 
thankful to Jayachandran Venkatesan for redrawing the chemical structures in the Figure 1. 
References  
1.  da Rocha, A.B.; Lopes, R.M.; Schwartsmann, G. Natural products in anticancer therapy. Curr. 
Opin. Pharmacol. 2001, 1, 364–369. 
2.  McCullagh, M. Natural product pharmaceuticals-the third generation. Drug Disc. World 2008. 
Available online:  http://www.ddw-online.com/drug_discovery/258437/natural_product_ 
pharmaceuticals_the_third_generation.html (accessed on 25 August 2009). 
3.  Pallela, R.; Yoon, N.-Y.; Kim, S.K. Anti-photoaging and photoprotective compounds derived 
from marine organisms. Mar. Drugs 2010, 8, 1189–1202. 
4.  Mayer, A.M.; Rodríguez, A.D.; Berlinck, R.G.; Hamann, M.T. Marine pharmacology in 2005–6: 
Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, 
antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, 
immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. 
Acta 2009, 1790, 283–308. 
5.  Hickford, S.J.; Blunt, J.W.; Munro, M.H. Antitumour polyether macrolides: Four new 
halichondrins from the New Zealand deep-water marine sponge Lissodendoryx sp. Bioorg. Med. 
Chem. 2009, 17, 2199–2203. 
6.  Aoki, S.; Cao, L.; Matsui, K.; Rachmat, R.; Akiyama, S.-i.; Kobayashi, M. Kendarimide A, a 
novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a 
marine sponge of Haliclona sp. Tetrahedron 2004, 60, 7053–7059. 
7.  Thomas, T.R.A.; Kavlekar, D.P.; LokaBharathi, P.A. Marine Drugs from Sponge-Microbe 
Association—A Review. Mar. Drugs 2010, 8, 1417–1468 
8.  Rodriguez, A.D.; Martinez, N. Marine antitumor agents: 14-deoxycrassin and pseudoplexaurol, 
new cembranoid diterpenes from the Caribbean gorgonian Pseudoplexaura porosa. Experientia 
1993, 49, 179–181. Mar. Drugs 2010, 8                 
 
 
2715
9.  Olano, C.; Méndez, C.; Salas, J.A. Antitumor Compounds from Marine Actinomycetes.  Mar. 
Drugs 2009, 7, 210–248. 
10.  Hassan, H.M.; Khanfar, M.A.; Elnagar, A.Y.; Mohammed, R.; Shaala, L.A.; Youssef, D.T.; 
Hifnawy, M.S.; El Sayed, K.A. Pachycladins A–E, prostate cancer invasion and migration 
inhibitory Eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados. J. Nat. 
Prod. 2010, 73, 848–853. 
11.  Maloney, K.N.; Macmillan, J.B.; Kauffman, C.A.; Jensen, P.R.; Dipasquale, A.G.; Rheingold, 
A.L.; Fenical, W. Lodopyridone, a structurally unprecedented alkaloid from a marine 
actinomycete. Org. Lett. 2009, 11, 5422–5424. 
12.  Tapiolas, D.M.; Roman, M.; Fenical, W.; Stout, T.J.; Clardy, J. Octalactins A and B: cytotoxic 
eight-membered-ring lactones from a marine bacterium, Streptomyces sp. J. Am. Chem. Soc. 
1991, 113, 4682–4683. 
13.  Gorajana, A.;Venkatesan, M.; Vinjamuri, S.; Kurada, V.V.S.N.B.; Peela, S.; Jangam, P.; Poluri, 
E.; Zeeck, A. Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces 
chibaensis AUBN1/7. Microbiol. Res. 2007, 162, 322–327. 
14.  Du, L.; Zhu, T.; Fang, Y.; Liu, H.; Gu, Q.; Zhu, W. Aspergiolide A, a novel anthraquinone 
derivative with naphtho(1,2,3-de)chromene-2,7-dione skeleton isolated from a marine-derived 
fungus Aspergillus glaucus. Tetrahedron 2007, 63, 1085–1088. 
15.  Hawas, U.W.; Shaaban, M.; Shaaban, K.A.; Speitling, M.; Maier, A.; Kelter, G.; Fiebig, H.H.; 
Meiners, M.; Helmke, E.; Laatsch, H. Mansouramycins A–D, cytotoxic isoquinolinequinones 
from a marine streptomycete. J. Nat. Prod. 2009, 72, 2120–2124. 
16.  Rickards, R.W.; Rothschild, J.M.; Willis, A.C.; de Chazal, N.M.; Kirk, J.; Kirk, K.; Saliba, K.J.; 
Smith, G.D. Calothrixins A and B, novel pentacyclic metabolites from Calothrix cyanobacteria 
with potent activity against malaria parasites and human cancer cells. Tetrahedron  1999,  55, 
13513. 
17.  Du, L.; Feng, T.; Zhao, B.; Li, D.; Cai, S.; Zhu, T.; Wang, F.; Xiao, X.; Gu, Q. Alkaloids from a 
deep ocean sediment-derived fungus Penicillium sp. and their antitumor activities. J. Antibiot. 
2010, 63, 165–170. 
18.  Asolkar, R.N.; Jensen, P.R.; Kauffman, C.A.; Fenical, W. Daryamides A–C, Weakly Cytotoxic 
Polyketides from a Marine-Derived Actinomycete of the Genus Streptomyces Strain CNQ-085. J. 
Nat. Prod. 2006, 69, 1756–1759. 
19.  Tan, L.T. Bioactive natural products from marine cyanobacteria for drug discovery. 
Phytochemistry 2007, 68, 954–979. 
20.  Mayer, A.M.S.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; 
Newman, D.J.; Potts, B.C.; Shuster D.E. The odyssey of marine pharmaceuticals: a current 
pipeline perspective. Trends Pharmacol. Sci. 2010, 31(6), 255–265. 
21.  Cho, J.Y.; Williams, P.G.; Kwon, H.C.; Jensen, P.R.; Fenical, W. Lucentamycins A-D, cytotoxic 
peptides from the marine-derived actinomycete Nocardiopsis lucentensis. J. Nat. Prod. 2007, 70, 
1321–1328. 
22.  Pérez, M.; Crespo, C.; Schleissner, C.; Rodríguez, P.; Zúñiga, P.; Reyes, F. Tartrolon D, a 
cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069. 
J. Nat. Prod. 2009, 72, 2192–2194. Mar. Drugs 2010, 8                 
 
 
2716
23.  Koizumi, Y.; Arai, M.; Tomoda, H.; Omura, S. Oxaline, a fungal alkaloid, arrests the cell cycle in 
M phase by inhibition of tubulin polymerization. Biochim. Biophys. Acta. 2004, 1693, 47–55. 
24.  Bringmann, G.; Gulder, T.A.; Lang, G.; Schmitt, S.; Stöhr, R.; Wiese, J.; Nagel, K.; Imhoff, J.F. 
Large-scale biotechnological production of the antileukemic marine natural product 
sorbicillactone A. Mar. Drugs 2007, 5, 23–30. 
25.  Kwon, H.C.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Marinomycins A–D, Antitumor-
Antibiotics of a New Structure Class from a Marine Actinomycete of the Recently Discovered 
Genus “Marinispora”. J. Am. Chem. Soc. 2006, 128, 1622–1632. 
26.  Lee, M.; Murphy, G. Matrix metalloproteinases at a glance. J. Cell Sci. 2004, 117, 4015–4016. 
27.  Gill, S.; Parks, W. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. 
Biochem. Cell Biol. 2008, 40, 1334–1347. 
28.  Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinase in cancer progression. Nat. 
Rev. Cancer 2002, 2, 161–174.  
29.  Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-
trial era. Nat. Rev. Cancer 2002, 2, 657–672. 
30.  Chen, Z.; Kim, S.K. Matrix Metalloproteinase Inhibitors (MMPIs) from Marine Natural Products: 
the Current Situation and Future Prospects. Mar. Drugs 2009, 7, 71–84. 
31.  Kim, M.M.; Kim, S.K. Chitooligosaccharides inhibit activation and expression of matrix 
metalloproteinase-2 in human dermal fibroblasts. FEBS Lett. 2006, 580, 2661–2666. 
32.  Van Ta, Q.; Kim, M.M.; Kim, S.K. Inhibitory effect of chitooligosaccharides on matrix 
metalloproteinase-9 in human fibrosarcoma cells (HT1080). Mar. Biotechnol. 2006, 8, 593–599. 
33.  Rajapakse, N.; Kim, M.M.; Mendis, E.; Huang, R.H.; Kim, S.K. Carboxylated 
chitooligosaccharides (CCOS) inhibit MMP-9 expression in human fibrosarcoma cells via down-
regulation of AP-1. Biochim. Biophys. Acta 2006, 1760, 1780–1788.  
34.  Wang, S.B.; Cheng, Y.N.; Wang, F.S.; Sun, L.R.; Liu, C.H.; Chen, G.J.; Li, Y.H.; Ward, S.G.; 
Qu, X.J. Inhibition activity of sulfated polysaccharide of Sepiella maindroni ink on matrix 
metalloproteinase (MMP)-2. Biomed. Pharmacother. 2008, 62, 297–302.  
35.  Kim, M.M.; van Ta, Q.; Mendis, E.; Rajapakse, N.; Jung, W.K.; Byun, H.G.; Jeon, Y.J.; Kim, 
S.K. Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Sci. 
2006, 79, 1436–1443. 
36.  Semenza, G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. 
Med. 2002, 8(Suppl.), S62-S67. 
37.  Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular 
aspects. J. Natl. Cancer Inst. 2001, 93, 266–276. 
38.  Semenza, G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. 
Trends Mol. Med. 2001, 7, 345–350.  
39.  Kung, A.L.; Wang, S.; Klco, J.M.; Kaelin, W.G.; Livingston, D.M. Suppression of tumor growth 
through disruption of hypoxia-inducible transcription. Nat. Med. 2000, 6, 1335–1340. 
40.  Mohammed, K.A.; Hossain, C.F.;
  Zhang, L.; Bruick, R.K.; Zhou, Y.D.; Nagle, D.G. 
Laurenditerpenol, a New Diterpene from the Tropical Marine Alga Laurencia intricata that 
Potently Inhibits HIF-1 Mediated Hypoxic Signaling in Breast Tumor Cells. J. Nat. Prod. 2004, 
67, 2002–2007. Mar. Drugs 2010, 8                 
 
 
2717
41.  Liu, R.; Liu, Y.; Zhou, Y.D.; Nagle, D.G Molecular-Targeted Antitumor Agents 15: 
Neolamellarins from the Marine Sponge Dendrilla nigra Inhibit Hypoxia-Inducible Factor-1 
(HIF-1) Activation and Secreted Vascular Endothelial Growth Factor (VEGF) Production in 
Breast Tumor Cells. J. Nat. Prod. 2007, 70, 1741–1745. 
42.  Liu, Y.; Liu, R.; Mao, S.C.; Morgan, J.B.; Jekabsons, M.B.; Zhou, Y.D.; Nagle, D.G. Molecular-
Targeted Antitumor Agents. 19. Furospongolide from a Marine Lendenfeldia sp. Sponge Inhibits 
Hypoxia-Inducible Factor-1 Activation in Breast Tumor Cells. J. Nat. Prod. 2008, 71, 1854–1860. 
43.  Dai, J.; Liu, Y.; Jia, H.; Zhou, Y.D.; Nagle, D.G. Benzochromenones from the marine crinoid 
Comantheria rotula inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and 
differentially suppress the growth of certain tumor cell lines. J. Nat. Prod. 2007, 70, 1462–1466. 
44.  Hodges,
 T.W.; Hossain,
 C.F.; Kim, Y.P.; Zhou, Y.D.; Nagle, D.G. Molecular-Targeted Antitumor 
Agents: The Saururus cernuus Dineolignans Manassantin B and 4-O-Demethylmanassantin B Are 
Potent Inhibitors of Hypoxia-Activated HIF-1. J. Nat. Prod. 2004, 67, 767–771. 
45.  Nagle, D.G.; Zhou, Y.D. Marine natural products as inhibitors of hypoxic signaling in tumors. 
Phytochem. Rev. 2009, 8, 415–429. 
46.  Keutgens, A.; Robert, I.; Viatour, P.; Chariot, A. Deregulated NF-kB activity in haemological 
malignancies. Biochem. Pharmacol. 2006, 72, 1069–1080. 
47.  Baldwin, A.S. The NF-B and I B proteins: new discoveries and insights. Annu. Rev. Immunol. 
1996, 14, 649–683. 
48.  Folmer, F.; Jaspars, M.; Dicato, M.; Diederich, M. Marine natural products as targeted modulators 
of the transcription factor NF-kappa B. Biochem. Pharmacol. 2008, 75, 603–617. 
49.  Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.J.; Fenical, W. 
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a 
marine bacterium of the new genus Salinospora. Angew. Chem. 2003, 42, 355–357. 
50.  Asolkar, R.N.; Freel, K.C.; Jensen, P.R.; Fenical, W.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, J.M. 
Arenamides A-C, cytotoxic NFkappaB inhibitors from the marine actinomycetes Salinispora 
arenicola. J. Nat. Prod. 2009, 72, 396–402. 
51.  Nam, S.J.; Gaudêncio, S.P.; Kauffman, C.A.; Jensen, P.R.; Kondratyuk, T.P.; Marler, L.E.; 
Pezzuto, J.M.; Fenical, W. Fijiolides A and B, inhibitors of TNF-alpha-induced NFkappaB 
activation, from a marine-derived sediment bacterium of the genus Nocardiopsis. J. Nat. Prod. 
2010, 73, 1080–1086. 
52.  Schumacher, M.; Cerella, C.; Eifes, S.; Chateauvieux, S.; Morceau, F.; Jaspars, M.; Dicato, M.; 
Diederich, M. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B 
activation through proteasome inhibition and induces apoptotic cell death. Biochem. Pharmacol. 
2010, 79, 610–622. 
53.  Champoux, J.J. DNA Topoisomerases: Structure, Function, and Mechanism. Ann. Rev. Biochem. 
2001, 70, 369–413. 
54.  Dias, N.; Vezin, H.; Lansiaux, A.; Bailly, C. Topoisomerase Inhibitors of Marine Origin and 
Their Potential Use as Anticancer Agents. Top. Curr. Chem. 2005, 253, 89–108. Mar. Drugs 2010, 8                 
 
 
2718
55.  Bonnard, I.; Bontemps, N.; Lahmy, S.; Banaigs, B.; Combaut, G.; Francisco, C.; Colson, P.; 
Houssier, C.; Waring, M.J.; Bailly, C. Binding to DNA and cytotoxic evaluation of ascididemin, 
the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei. Anticancer Drug Des. 
1995, 10, 333–346. 
56.  Dassonneville, L.; Wattez, N.; Baldeyrou, B.; Mahieu, C.; Lansiaux, A.; Banaigs, B.; Bonnard, I.; 
Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of 
apoptosis in leukemia cells. Biochem Pharmacol. 2000, 60(4), 527–537. 
57.  Tardy, C.; Facompré, M.; Laine, W.; Baldeyrou, B.; García-Gravalos, D.; Francesch, A.; Mateo, 
C.; Pastor, A.; Jiménez, J.A.; Manzanares, I.; Cuevas, C.; Bailly, C. Topoisomerase I-mediated 
DNA cleavage as a guide to the development of antitumor agents derived from the marine 
alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg. Med. Chem. 
2004, 12(7), 1697–1712. 
58.  Gorin, M.A.; Pan, Q. Protein kinase Cε: an oncogene and emerging tumor biomarker. Mol. 
Cancer 2009, 8, 9. 
59.  Pettit, G.R.; Herald, C.L.; Doubek, D.L.; Herald, D.L.; Arnold, E.; Clardy, J. Isolation and 
structure of bryostatin 1. J. Am. Chem. Soc. 1982, 104, 6846–6848. 
60.  Mutter, R.; Wills, M. Chemistry and Clinical Biology of the Bryostatins. Bioorg. Med. Chem. 
2000, 8, 1841–1860. 
61.  Kortmansky, J.; Schwartz, G.K. Bryostatin-1: A novel PKC inhibitor in clinical development. 
Cancer Invest. 2003, 21, 924–936. 
62.  Keck, G.E.; Poudel, Y.B.; Welch, D.S.; Kraft, M.B.; Truong, A.P.; Stephens, J.C.; Kedei, N.; 
Lewin, N.E.; Blumberg, P.M. Substitution on the A-ring confers to bryopyran analogues the 
unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters. 
Org. Lett. 2009, 11, 593–596. 
63.  Jackson, K.L.; Henderson, J.A., Phillips, A.J. The Halichondrins and E7389. Chem. Rev. 2009, 
109(7), 3044–3079. 
64.  Okouneva, T.; Azarenko,
 O.; Wilson, L.; Littlefield, B.A.; Jordan, M.A. Inhibition of centromere 
dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008, 7, 2003–2011.  
65.  Watanabe, J.; Natsume, T.; Kobayashi, M. Comparison of the antivascular and cytotoxic activities 
of TZT-1027 (Soblidotin) with those of other anticancer agents. Anticancer Drugs  2007,  18,  
905–911. 
66.  Mitsiades, C.S.; Ocio, E.M.; Pandiella, A.; Maiso, P.; Gajate, C.; Garayoa, M.; Vilanova, D.; 
Montero, J.; Mitsiades, N.; McMullan, C.J.; Munshi, N.C.; Hideshima, T.; Chauhan, D.; Aviles, 
P.; Otero, G.; Faircloth, G.; Mateos, M.V.; Richardson, P.G.; Mollinedo, F.; San-Miguel, J.F.; 
Anderson, K.C. Aplidin, a marine organism-derived compound with potent antimyeloma activity 
in vitro and in vivo. Cancer Res. 2008, 68, 5216–5225. 
67.  Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.; Sekiya, 
H.; Uno, I. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus 
ustus. Bioorg. Med. Chem. Lett. 1997, 7, 2847–2852. 
68.  Nicholson, B.; Lloyd, G.K.; Miller, B.R.; Palladino, M.A.; Kiso, Y.; Hayashi, Y.; Neuteboom, 
S.T. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor 
vascular-disrupting agent. Anticanc. Drugs 2006, 17, 25–31. Mar. Drugs 2010, 8                 
 
 
2719
69.  Davidson, S.K.; Allen, S.W.; Lim, G.E.; Anderson, C.M.; Haygood, M.G. Evidence for the 
biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the 
bryozoan Bugula neritina. Appl. Environ. Microbiol. 2001, 67, 4531–4537. 
70.  Thakur, N.L.; Thakur, A.L. Marine Biotechnology: an overview. Ind. J. Biotechnol. 2006, 5,  
263–268. 
71.  Nereus Pharmaceuticals homepage. Available online: http://www.nereuspharm.com/ 
overview.shtml (accessed on 02 July 2010). 
72.  Schwartsmann, G.; Da Rocha, A.B.; Berlinck, R.G.; Jimeno, J. Marine organisms as a source of 
new anticancer agents. Lancet Oncol. 2001, 2, 221–225.  
73.  Wang Y.; Lyu, Y.L.; Wang, J.C. Dual localization of human DNA topoisomerase IIIalpha to 
mitochondria and nucleus. Proc. Natl. Acad. Sci. USA 2002, 99, 12114–12119. 
74.  Goulaouic, H.; Roulon, T.; Flamand, O.; Grondard, L.; Lavelle, F.; Riou, J.F. Purification and 
characterization of human DNA topoisomerase III alpha. Nucleic Acids Res. 1999,  27,  
2443–2450. 
75.  Swami, M. Hypoxia: The HIF2α puzzle. Nat. Rev. Cancer 2010, 10, 603. 
76.  Lam, K.S. Discovery of novel metabolites from marine actinomycetes. Curr. Opin. Microbiol. 
2006, 9, 245–251.  
77.  Bull, A.T.; Ward, A.C.; Goodfellow. M. Search and discovery strategies for biotechnology: the 
paradigm shift. Microbiol. Mol. Biol. Rev. 2000, 64, 573–606. 
78.  Hanash, S.; Taguchi, A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 
2010, 10, 652–660. 
79.  Chittiboyina, A.G.; Kumar, G.M.; Carvalho, P.B.; Liu, Y.; Zhou, Y.D.; Nagle, D.G.; Avery, M.A. 
Total synthesis and absolute configuration of laurenditerpenol: a HIF-1 activation inhibitor. J. 
Med. Chem. 2007, 50, 6299–6302. 
80.  Jung, M.E., Im, G.Y.J. Convergent total synthesis of the racemic HIF-1 inhibitor laurenditerpenol. 
Tetrahedron Lett. 2008, 49, 4962–4964. 
81.  Bhadury, P.; Mohammad, B.T.; Wright, P.C. The current status of natural products from marine 
fungi and their potential as anti-infective agents. J. Ind. Microbiol. Biotechnol.  2006,  33,  
325–337. 
82.  Newman, D.J.; Hill, R.T. New drugs from marine microbes: the tide is turning. J. Ind. Microbiol. 
Biotechnol. 2006, 33, 539–544. 
83.  Belofsky, G.N.; Jensen, P.R.; Fenical, W. Sansalvamide: A new cytotoxic cyclic depsipeptide 
produced by a marine fungus of the genus Fusarium. Tetrahedron Lett. 1999, 40, 2913–2916.  
84.  Raghukumar, C. Marine fungal biotechnology: an ecological perspective. Fungal Divers. 2008, 
31, 19–35. 
85.  Moradali, M.F.; Mostafavi, H.; Ghods, S.; Hedjaroude, G.A. Immunomodulating and anticancer 
agents in the realm of macromycetes fungi (macrofungi). Int. Immunopharmacol.  2007,  7,  
701–724. 
86.  Xie, S.; Xiao, J.; Xu, J. Advance in microbial ribosome engineering. Wei Sheng Wu Xue Bao. 
2009, 49, 981–986. Mar. Drugs 2010, 8                 
 
 
2720
87.  Andersen, J.N.; Sathyanarayanan, S.; Di Bacco, A.; Chi, A.; Zhang, T.; Chen, A.H.; Dolinski, B.; 
Kraus, M.; Roberts, B.; Arthur, W.; Klinghoffer, R.A.; Gargano, D.; Li, L.; Feldman, I.; Lynch, 
B.; Rush, J., Hendrickson, R.C.; Blume-Jensen, P.; Paweletz, C.P. Pathway-based identification of 
biomarkers for targeted therapeutics: Personalized oncology with PI3K pathway inhibitors. Sci. 
Transl. Med. 2010, 2, 43ra55. 
88.  Borkakoti, N. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. 
Transactions 2004, 32, 17–20. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 